Key Advance Toward Treatment For Most Common Adult Form Of Muscular Dystrophy - Journal Of The American Chemical Society
In the study, Benjamin Miller and colleagues point out that MMD differs from typical hereditary diseases. They result from mutated DNA in genes that encodes an erroneous message that RNA picks up and passes along. As a result, cells produce faulty proteins. Those proteins disrupt cells' activity and cause symptoms of the disease. Rather, MMD is caused by wayward or "toxic" strands of RNA.
The researchers describe discovery of a family of drug-like molecules that target the errant strands of RNA, preventing production of the defective protein. The discovery, they said, provides scientists for the first time with substances that target the root cause of MMD and represent molecules that could be developed into drugs. They note that drugs more commonly target DNA or proteins, with the RNA approach offering a different and potentially valuable route to developing new medications for certain diseases.
"Dynamic combinatorial selection of molecules capable of Inhibiting the (CUG) Repeat RNA - MBNL1 interaction in vitro: Discovery of lead compounds targeting myotonic dystrophy (DM1)"
DOWNLOAD FULL TEXT ARTICLE
Journal of the American Chemical Society
American Chemical Society
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
American Chemical Society. "Key Advance Toward Treatment For Most Common Adult Form Of Muscular Dystrophy - Journal Of The American Chemical Society." Medical News Today. MediLexicon, Intl., 25 Nov. 2008. Web.
9 Dec. 2016. <http://www.medicalnewstoday.com/releases/130725.php>
American Chemical Society. (2008, November 25). "Key Advance Toward Treatment For Most Common Adult Form Of Muscular Dystrophy - Journal Of The American Chemical Society." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.